Literature DB >> 6490733

Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake.

L M Pfeffer, I Tamm.   

Abstract

Replenishment of medium after 72 hr of growth of HeLa-S3 cells in dense suspension cultures increased [3H]-thymidine uptake into cells and incorporation into DNA, with the levels reaching a peak approximately 12 hr following medium change; beta interferon inhibits the enhanced uptake of [3H]-thymidine and labeling of DNA in a dose-dependent manner. Some reduction in these processes is observed at a concentration as low as 1 u/ml, and approximately 75% inhibition at 640 u/ml. Kinetic analysis has revealed that the rate of labeling of the acid-soluble pool with [3H]-thymidine, measured either at 22 degrees C or 37 degrees C, is reduced in interferon-treated (640 u/ml, 24 hr) HeLa-S3 cells. At 22 degrees C, the initial rate of thymidine transport at a high (500 microM) thymidine concentration, determined within the first 30 sec of [3H]-thymidine addition was depressed by 44% in interferon-treated HeLa cells. At 37 degrees C, labeled precursors accumulate in acid-soluble material for approximately 8 min after the addition of [3H]-thymidine, after which an apparent equilibrium level is attained. At this temperature, the rate of thymidine uptake and the apparent equilibrium level attained were depressed by 70% in interferon-treated HeLa cells. The reduced incorporation of [3H]-thymidine into DNA in interferon-treated HeLa-S3 cells can be largely explained by interferon inhibition of thymidine transport and phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6490733     DOI: 10.1002/jcp.1041210223

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

Review 1.  Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.

Authors:  A J Schrader; Z Varga; A Hegele; S Pfoertner; P Olbert; R Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-25       Impact factor: 4.553

Review 2.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

3.  Extracellular matrix alters the relationship between tritiated thymidine incorporation and proliferation of MC3T3-E1 cells during osteogenesis in vitro.

Authors:  W J Peterson; K H Tachiki; D T Yamaguchi
Journal:  Cell Prolif       Date:  2002-02       Impact factor: 6.831

4.  Immune interferon inhibits proliferation and induces 2'-5'-oligoadenylate synthetase gene expression in human vascular smooth muscle cells.

Authors:  S J Warner; G B Friedman; P Libby
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.

Authors:  C M van Herpen; R L Jansen; W H Kruit; K Hoekman; G Groenewegen; S Osanto; P H De Mulder
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.

Authors:  A Piga; S Cascinu; L Latini; M Marcellini; M Bavosi; L Acito; R Bascioni; L Giustini; G Francini; A Pancotti; G Rossi; M Del Papa; F Carle; R Cellerino
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

7.  Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.

Authors:  A Ravaud; N Trufflandier; J M Ferrière; M Debled; J Palussière; L Cany; R Gaston; S Mathoulin-Pélissier; B N Bui
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.